Shanghai Rendu Biotechnology Stock Net Income
| 688193 Stock | 42.38 0.54 1.26% |
Shanghai Rendu Biotechnology fundamentals help investors to digest information that contributes to Shanghai Rendu's financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Rendu's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Rendu stock.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 8.3 M | 7.8 M | |
| Net Income | 8.3 M | 7.8 M |
Shanghai | Net Income |
Shanghai Rendu Biotechnology Company Net Income Analysis
Shanghai Rendu's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Shanghai Rendu Net Income | 8.26 M |
Most of Shanghai Rendu's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Rendu Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Shanghai Net Interest Income
Net Interest Income |
|
Based on the recorded statements, Shanghai Rendu Biotechnology reported net income of 8.26 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all China stocks is notably lower than that of the firm.
Shanghai Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Rendu's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Rendu could also be used in its relative valuation, which is a method of valuing Shanghai Rendu by comparing valuation metrics of similar companies.Shanghai Rendu is currently under evaluation in net income category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.0227 | ||||
| Return On Asset | -0.0062 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 40 M | ||||
| Shares Owned By Insiders | 60.13 % | ||||
| Shares Owned By Institutions | 5.87 % | ||||
| Price To Book | 1.83 X | ||||
| Price To Sales | 9.79 X | ||||
| Revenue | 164.41 M | ||||
| Gross Profit | 304.22 M | ||||
| EBITDA | 2.87 M | ||||
| Net Income | 8.26 M | ||||
| Total Debt | 2.93 M | ||||
| Book Value Per Share | 23.95 X | ||||
| Cash Flow From Operations | 17.19 M | ||||
| Earnings Per Share | 0.54 X | ||||
| Number Of Employees | 358 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 1.72 B | ||||
| Total Asset | 1.05 B | ||||
| Retained Earnings | 136.46 M | ||||
| Working Capital | 820.69 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 1.05 B | ||||
| Last Dividend Paid | 0.3 |
About Shanghai Rendu Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Rendu Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Rendu using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Rendu Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Rendu financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Rendu security.